...
首页> 外文期刊>Iranian Journal of Immunology >Serum Levels of Monocyte Chemoattractant Protein-1 Correlate with Poor Clinical Grades in Cerebral Aneurysms
【24h】

Serum Levels of Monocyte Chemoattractant Protein-1 Correlate with Poor Clinical Grades in Cerebral Aneurysms

机译:血清单核细胞趋化蛋白-1的水平与脑动脉瘤的临床水平差相关。

获取原文
           

摘要

Background : Ruptured cerebral aneurysms (ICAs) are the most common non-traumatic cause of subarachnoid hemorrhage (SAH) that is associated with life threatening complications such as Vasospasm, Infarction, and Hydrocephalus (HCP). The active participation of macrophage/monocyte-mediated inflammatory response in the pathogenesis of cerebral aneurysm as labeled with Monocyte ChemoattractantProtein-1 (MCP-1) is suggested. Objective: To measure the serum level of MCP-1 in ruptured CAs in different time intervals . Methods: We measured the serum levels of MCP-1 in SAH patients who had CAs and compared it with that of MCP-1 in two control groups: including patients with SAH without CAs, and the normal population of blood donors. We also measured the MCP-1 levels in patients with CAs one week afterward to evaluate the effect of treatment. Serum level of MCP-1 was measured by a commercial ELISA assay. Results: Mean serum MCP-1 level in patients with SAH and CAs was 188.2168 Pg/ml and 331.3982 Pg/ml in the normal population. There was no statistically significant difference between serum levels of MCP-1 on the first (mean=188.2168 Pg/ml) and 7 th days after SAH onset (mean=171.8450 Pg/ml) (p=0.739). Serum level of MCP-1 increased significantly as Glasgow Coma Scale decreased (p=0.078) and Hunt and Hess score increased (p=0.089). Conclusion: Our results did not show an increasing MCP-1 serum level in patients with aneurysmal SAH. There was a relationship between poor clinical grade and MCP-1 levels in patients with CAs. MCP-1 may be a local inflammatory marker for cerebral aneurysms without systemic manifestation.
机译:背景:破裂的脑动脉瘤(ICAs)是蛛网膜下腔出血(SAH)的最常见非创伤性原因,与诸如血管痉挛,梗塞和脑积水(HCP)等危及生命的并发症相关。建议巨噬细胞/单核细胞介导的炎症反应在单核细胞趋化蛋白-1(MCP-1)标记的脑动脉瘤发病机制中的积极参与。目的:测定不同时间间隔破裂的CA中MCP-1的血清水平。方法:我们测量了具有CAs的SAH患者的MCP-1血清水平,并将其与MCP-1的两个对照组进行了比较:两个对照组包括没有CAs的SAH患者和正常的献血者。一周后,我们还测量了CA患者的MCP-1水平,以评估治疗效果。通过商业ELISA测定法测量MCP-1的血清水平。结果:正常人群中SAH和CAs患者的平均MCP-1水平为188.2168 Pg / ml和331.3982 Pg / ml。在SAH发作的第一天(平均= 188.2168 Pg / ml)和第七天(平均= 171.8450 Pg / ml),MCP-1的血清水平之间无统计学差异(p = 0.739)。随着格拉斯哥昏迷评分的降低(p = 0.078)和亨特和赫斯评分的提高(p = 0.089),MCP-1的血清水平显着增加。结论:我们的结果未显示动脉瘤SAH患者的MCP-1血清水平升高。 CAs患者的临床不良评分与MCP-1水平之间存在关联。 MCP-1可能是没有系统表现的脑动脉瘤的局部炎症标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号